The current state of hormonal therapy for prostate cancer

Ca-A Cancer Journal for Clinicians

Volumn 52, Issue 3, 2002, Pages 154-179

  Hellerstedt, Beth A ^a   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ESTROGEN; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN ANTAGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; NILUTAMIDE; PAMIDRONIC ACID; PC SPES; PHOSPHORIC ACID DERIVATIVE; PLACEBO; SEX HORMONE; TESTOSTERONE; UNINDEXED DRUG; VENLAFAXINE; ZOLEDRONIC ACID;

ANEMIA; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; FATIGUE; GYNECOMASTIA; HORMONE INHIBITION; HOT FLUSH; HUMAN; LIVER TOXICITY; MALE; MEDICAL DECISION MAKING; METASTASIS; MUSCLE ATROPHY; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; SEXUAL DYSFUNCTION; WEIGHT GAIN;

EID: 0036112592     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.52.3.154     Document Type: Article

References (101)

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
2. The results of double castration in hypertrophy of the prostate
3. Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphates in metastatic carcinoma of the prostate
4. Prostatic carcinoma, follow-up on 795 patients treated prior to endocrine era and comparison of survival rates between these and patients treated by endocrine therapy
5. Endocrine control of prostatic carcinoma, clinical and statistical survey of 1,818 cases
6. Carcinoma of the prostate: Treatment comparisons
7. Treatment and survival of patients with cancer of the prostate
8. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo
9. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate
10. Orchiectomy for advanced prostatic carcinoma: A re-evaluation
11. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate
12. Medical or surgical orchidectomy: The patients' choice
13. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study
14. Living with treatment decisions: Regrets and quality of life among men treated for metastatic prostate cancer
15. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastati
16. A phase III open randomized study of Zoladex 3.6 mg depot versus DES 3 mg per day in untreated advanced prostate cancer:A West Midlands Urological Research Group Study
17. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma
18. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial
19. Phase III randomized study of zoladex versus stilboestrol in the treatment of advanced prostate cancer
20. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
21. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol
22. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: Final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer
23. Comparison of diethylstilbestrol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: Final analysis of a randomized phase III trial of the European Organization for Research on Treatment of
24. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer
25. Use of cyproterone acetate in prostate cancer
26. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996
27. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer
28. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
29. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
30. Two herbal supplements recalled amid rising regulatory concerns; health: One is a popular treatment for prostate cancer that has shown promise in testing
31. State health director warns consumers about prescription drugs in herbal products
32. Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma
33. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
34. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853)
35. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer
36. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
37. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
38. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results
39. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer
40. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up
41. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects
42. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer
43. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
44. Antiandrogen monotherapy: A new form of treatment for patients with prostate cancer
45. Randomized multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery: Interim analysis of treatment effect and prognostic factors
46. The bicalutamide Early Prostate Cancer Program: Demography
47. Adjuvant hormone therapy after radical prostatectomy: Indications and results
48. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
49. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
50. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
51. RTOG Protocol 92-02: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
52. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
53. Subset analysis of RTOG 85-31 and 86-10 indicates an advantages for long-term versus short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy
54. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer
55. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation
56. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy
57. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy
58. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy
59. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies
60. Estrogens in the treatment of prostate cancer
61. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial
62. Immediate versus deferred hormone therapy for prostate cancer: How safe is androgen deprivation?
63. Fatigue in patients with prostate cancer receiving hormone therapy
64. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer
65. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy
66. Side effects of endocrine treatment and their mechanisms: Castration, antiandrogens, and estrogens
67. Diethylstilbestrol in treatment of post orchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone
68. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate
69. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer
70. Androgen independent prostate cancer: The evolving role of chemotherapy
71. Potential side-effects of endocrine treatment of long duration in prostate cancer
72. Long term side effects of intermittent androgen suppression therapy in prostate cancer: Results of a phase II study
73. A comparison of the prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies: Preliminary report
74. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
75. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
76. Zoledronic acid is effective in treatment of bone metastases from prostate cancer: Results of a large, phase III, double-blind, randomized trial
77. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
78. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
79. Intermittent endocrine therapy for advanced prostate cancer
80. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model
81. Intermittent androgen blockade in prostate cancer: Rationale and clinical experience
82. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations
83. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience
84. Impact of intermittent androgen deprivation on quality of life
85. Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients
86. Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects
87. Combined finasteride and flutamide therapy in men with advanced prostate cancer
88. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland
89. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
90. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed
91. Antiandrogen monotherapy: A new form of treatment for patients with prostate cancer
92. Prostate cancer and the geriatric patient
93. Clinical and economic considerations in the treatment of prostate cancer
94. The cost of bilateral orchidectomy as a treatment for prostatic carcinoma
95. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer
96. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer
97. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences
98. Complete androgen blockade for phosphate cancer: What went wrong?
99. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality